Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

viatris limited - bésilate de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - agents antithrombotiques - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). Élévation du segment st infarctus aigu du myocarde, en association avec de l'aas dans traitée médicalement les patients éligibles à un traitement thrombolytique. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. pour de plus amples informations, veuillez vous reporter à la section 5.

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - celecoxibum - gélules - celecoxibum 100 mg, lactosum monohydricum 149.7 mg, natrii laurilsulfas, povidonum k 30, carmellosum natricum conexum, magnesii stearas, kapselhülle: gelatina, e 171, drucktinte: lacca, propylenglycolum, e 132, pro capsula corresp., natrium 0.71 mg. - sélectif de la cox-2 inhibiteurs de la - synthetika

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - celecoxibum - gélules - celecoxibum 200 mg, lactosum monohydricum 49.8 mg, natrii laurilsulfas, povidonum k 30, carmellosum natricum conexum, magnesii stearas, kapselhülle: gelatina, e 171, drucktinte: lacca, propylenglycolum, e 172 (flavum), pro capsula corresp., natrium 0.71 mg. - sélectif de la cox-2 inhibiteurs de la - synthetika

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - macrogolum 3350, natrii chloridum, natrii hydrogenocarbonas, kalii chloridum - poudre orale en tant que solution - macrogolum 3350 13.125 g, natrii chloridum 350.7 mg, natrii hydrogenocarbonas 178.5 mg, kalii chloridum 46.6 mg, acesulfamum kalicum, aromatica (zitrone), ad pulverem pro charta corresp. natrium 187 mg. - la constipation opiniâtre, koprostase - synthetika

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - sildenafilum - comprimés pelliculés - sildenafilum 20.00 mg ut sildenafili citras, cellulosum microcristallinum, calcii hydrogenophosphas, carmellosum natricum conexum corresp. natrium 0.6 mg, magnesii stearas, Überzug: hypromellosum, e 171, lactosum monohydricum 0.735 mg, triacetinum, pro compresso obducto. - traitement de l'hypertension artérielle pulmonaire (hypertension pulmonaire primitive, ainsi que des maladies des tissus conjonctifs associés pah) de l'oms classe ii et iii, à l'amélioration de la performance physique - synthetika

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - sildenafilum - comprimés pelliculés - sildenafilum 25 mg pour sildenafili citras, color.: e 132, excipiens pro compresso de la brume. - dysfonction Érectile - synthetika

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - sildenafilum - comprimés pelliculés - sildenafilum 50 mg à sildenafili citras, color.: e 132, excipiens pro compresso de la brume. - dysfonction Érectile - synthetika

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - sildenafilum - comprimés pelliculés - sildenafilum 100 mg à sildenafili citras, color.: e 132, excipiens pro compresso de la brume. - dysfonction Érectile - synthetika

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - cholecalciferolum, de calcium - comprimés pelliculés - cholecalciferolum 800 u.i., calcii carbonas 1261 mg corresp. calcium 500 mg, maltodextrinum, carmellosum natricum conexum, silica colloidalis anhydrica, magnesii stearas, triglycerida media, amylum modificatum, saccharum 1.75 mg, silica colloidalis anhydrica, e 301, e 307, Überzug: hypromellosum, macrogolum 6000, paraffinum solidum syntheticum, pro compresso obducto corresp. natrium 3.2 mg. - de calcium et de vitamine d-préparation - synthetika

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - amlodipinum - comprimés - amlodipinum 5 mg ut amlodipini besilas, cellulosum microcristallinum, calcii hydrogenophosphas, carboxymethylamylum natricum a corresp. natrium 168 µg, magnesii stearas, pro compresso. - calciumantagonist - synthetika